## **GUJARAT TECHNOLOGICAL UNIVERSITY**

B.PHARM - SEMESTER-7 EXAMINATION - SUMMER-2024

Subject Code:BP702TTDate: 02/05/202			
Subject Name: Industrial Pharmacy IITime: 02.30 p.m. to 5.30 p.m.Total Marks: 80Instructions:			
<ol> <li>Attempt any five questions.</li> <li>Make suitable assumptions wherever necessary.</li> <li>Figures to the right indicate full marks.</li> </ol>			
Q.1	(a)	What is pilot plan study? Discuss objective and steps for pilot plan scale up study.	06
	(b) (c)	Write a detailed note on various level of changes in SUPAC guidelines. Discuss platform technology for scale up techniques with appropriate examples.	05 05
Q.2	(a) (b) (c)	Define IND. What information is to submitted with IND application? How can IND application be withdraw? Justify role of biostatistics in Pharmaceutical product development Discuss general consideration for space requirement for scale up techniques.	06 05 05
Q.3	(c) (a) (b) (c)	Describe the responsibility of regulatory affairs professionals Mention the goals of NDA. Discuss the general requirements for filing NDA. Describe the content and format of NDA.	06 05 05 05
Q.4	(a) (b) (c)	Describe the organization and responsibilities of CDSCO. Explain Regulatory requirements and approval procedures for New drug. Write a note on Certificate of Pharmaceutical Product.	06 05 05
Q.5	(a) (b) (c)	Explain benefits and key elements QbD. Write short note on Six sigma as a tool for quality management. Explain ISO 9000 series of quality systems standards for pharmaceutical product.	06 05 05
Q. 6	(a) (b) (c)	Give classification, advantage and disadvantages of technology transfer. What is granularity? Discuss the consideration in the granularity of TT process? What is SUPAC? Give SUPAC guidelines for modified release dosages form.	06 05 05
Q.7	(a) (b) (c)	<ul> <li>Compare the following:</li> <li>a) Responsibilities of SU's and RU's</li> <li>b) Do's and Don't of TT agreements.</li> <li>Write in brief about APCTD and NRDC.</li> <li>Explain the principles of technology transfer. Discuss the technical and regulatory gap assessment during the process.</li> </ul>	06 05 05

\*\*\*\*\*